Rituximab treatment of collapsing C1q glomerulopathy: clinical and histopathological evolution
- 1 August 2008
- journal article
- case report
- Published by Springer Science and Business Media LLC in Pediatric Nephrology
- Vol. 23 (8), 1355-1361
- https://doi.org/10.1007/s00467-008-0781-6
Abstract
A 13-year-old girl with obesity and hyperinsulinism developed steroid-resistant nephrotic syndrome due to collapsing glomerulopathy with dominant C1q-containing mesangial immune deposits (CG/C1qN). She became overtly diabetic while receiving alternate-day prednisone and tacrolimus, requiring insulin injections. Despite the addition of mycophenolate mofetil to the treatment regimen, renal function subsequently declined. Rituximab (four weekly doses of 375 mg/m2) was tried 6 months after initial presentation and 3 months after weaning all glucocorticoids. Glomerular filtration rate (GFR) and proteinuria improved. Unexpectedly, blood sugar control normalized 6 weeks after antibody infusion. Rituximab was readministered 20 months after the first course because of deteriorating renal function, but the effect on GFR and proteinuria was modest. A retrospective analysis revealed that tubulointerstitial infiltrates present in the biopsies prior to treatment with rituximab contained numerous CD20+ and CD3+ (CD4 > CD8) lymphocyte aggregates. Rebiopsy 10 weeks after repeat rituximab therapy demonstrated the elimination of B-cell infiltrates and the apparent decrease of interstitial T-cell infiltrates, yet persistent, advanced global glomerulosclerosis, interstitial fibrosis and tubular atrophy. In conclusion, CG/C1qN was associated with B- and T-cell-rich tubulointerstitial infiltrates. B-cell-directed therapy delayed clinical progression during early disease but failed to prevent or ameliorate chronic changes, despite effective tissue B-cell clearance. The incidental resolution of diabetes was noted after rituximab treatment.Keywords
This publication has 40 references indexed in Scilit:
- Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible?Pediatric Nephrology, 2008
- The potential utility of B cell-directed biologic therapy in autoimmune diseasesRheumatology International, 2007
- Prehypertension Increases the Risk for Renal Arteriosclerosis in AutopsiesJournal of the American Society of Nephrology, 2007
- The Contribution of B Cells to Renal Interstitial InflammationThe American Journal of Pathology, 2007
- Rituximab therapy for steroid-dependent minimal change nephrotic syndromePediatric Nephrology, 2006
- Transient insulin-dependent diabetes mellitus in children with steroid-dependent idiopathic nephrotic syndrome during tacrolimus treatmentPediatric Nephrology, 2006
- B cells in the spotlight: innocent bystanders or major players in the pathogenesis of type 1 diabetesTrends in Endocrinology & Metabolism, 2006
- Clinicopathologic Correlation of C1q Nephropathy in ChildrenAmerican Journal of Kidney Diseases, 2006
- C1q nephropathy: features at presentation and outcomePediatric Nephrology, 2005
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999